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Introduction
DHTKD1 is the E1 component (E1a) of the 2-oxoadipate dehydrogenase complex (OADHc) that operates in L-lysine, L-hydroxylysine and L-tryptophan degradation and converts 2-oxoadipic acid (OA) into glutaryl-CoA ( Figure S1 ) (1-7). DHTKD1 is a homolog of 2-oxoglutarate dehydrogenase OGDH (~39% identity), the E1 component (E1o) of the 2-oxoglutarate dehydrogenase complex (OGDHc) that functions in the citric acid cycle. In general, 2-oxo acid dehydrogenase complexes have unique E1 and E2 components, but share the same E3 component. DHTKD1 and OGDH are an exception, because they share both the E2 (DLST) and E3 (DLD) components (4, 8) , which allows for functional and regulatory cross-talk between the citric acid cycle and L-lysine degradation (5, 8) .
Genetic studies have implicated DHTKD1 in the pathogenesis of several human diseases. Autosomal recessive mutants in DHTKD1 cause 2-aminoadipic and 2oxoadipic aciduria (AMOXAD; MIM 204750) (2, 3, 6) , a biochemical abnormality of questionable clinical significance that is characterized by the accumulation of 2aminoadipic acid (AAA) and OA (Figure S1) (9) . Autosomal dominant variants have been associated with Charcot-Marie-Tooth disease type 2Q (CMT2Q, MIM 615025) and eosinophilic esophagitis (EoE) (10) (11) (12) . There is currently no satisfactory pathophysiological mechanism that explains the observed pleiotropy of DHTKD1 variants. Structural studies that allow modeling the consequences of the observed amino acid substitutions may help to address this question. Homologous structures have been resolved for Escherichia coli E1o (sucA) and Mycobacterium smegmatis KGD (2oxoglurate decarboxylase) (13) (14) (15) , which respectively share 40% and 37% identity with DHTKD1. Both proteins adopt the common fold of thiamin diphosphate (ThDP)dependent 2-oxo acid dehydrogenases (16, 17) . 5 The function of OADHc is upstream of glutaryl-CoA dehydrogenase, the enzyme defective in glutaric aciduria type 1 (GA1; MIM 231670) (18) (19) (20) (21) . The limited clinical consequences of AMOXAD has led multiple investigators to hypothesize that inhibition of DHTKD1 is a potential therapeutic strategy to treat GA1 (2, 8, 22) . Unfortunately, the substantial substrate overlap between OGDHc and OADHc precludes a significant reduction in the accumulation of toxic substrates (8, 22) . Nevertheless, inhibitors are useful tools that will help shed light on this important metabolic pathway and can help us understand its role in several human diseases. Here we report the crystal structure of the first human DHTKD1 at 2.1 Å in complex with ThDP and identify the first drug-like inhibitors of the enzyme.
Results

Identification of substrate analogs as DHTKD1 inhibitors
In order to be able to screen for DHTKD1 inhibitors, we optimized an assay based on dichlorophenolindophenol (DCPIP) reduction ( Figure S2a ). We first assessed substrate specificity of DHTKD1 by measuring the activity with 2-oxoglutaric acid (OG), OA, 2oxopimelic acid (OP) and 2-oxosuberic acid (OS), which vary only in carbon chain length ( Figure 1) . Consistent with the genetic evidence and work by others (2, 4, 7) , we found that DHTKD1 has optimal activity with the canonical substrate OA ( Figure S1 ) and negligible activity with OG and OS. Interestingly, DHTKD1 also displayed activity with OP, a metabolite currently unknown in human metabolism. Although the affinity of DHTKD1 for OP was lower than for OA, the Vmax appeared higher with OP ( Figure 1a ).
As judged from the progress curves, the assay was nonlinear with initial velocity being the highest, which is common for these DCPIP-based assays. Remarkably, the activity with OA declined much more rapidly than the activity with OP ( Figure S2b ). Therefore, OP provides a better dynamic window in inhibitor screening assays.
Six out of the 23 selected substrate analogs were able to inhibit DHTKD1 (Table   S1 ). OG and OS inhibited DHTKD1 activity competitively (Figure 1b, Figure S2c and Table S1 ). These data indicate that while DHTKD1 prefers OA and OP as substrates, OG and OS are able to bind to the enzyme, which is consistent with previous work (4).
Vigabatrin, an anti-epileptic and irreversible transaminase inhibitor known to cause aminoadipic aciduria (23), did not inhibit DHTKD1, but its oxo analog 4-oxo-5-hexenoic acid inhibited DHTKD1 irreversibly ( Figure 1b ). OG, OS and 4-oxo-5-hexenoic acid had relatively low affinities for DHTKD1.
Phosphonic acids inhibit 2-oxo acid dehydrogenase complexes by forming a predecarboxylation nucleophilic adduct at the C2 thiazolium atom, the adduct resembling a transition state analog (24) (25) (26) . We evaluated the ability of succinyl-, glutaryl-, adipoyland pimeloyl-phosphonic acid to inhibit DHTKD1. Adipoylphosphonic acid was a highly effective and specific mixed competitive-noncompetitive inhibitor of DHTKD1 (Ki of 0.15±0.03M), whereas glutaryl-and pimeloylphosphonic acid were less effective and . This also establishes that it is the E1 component that is subject to inhibition by adipoylphosphonic acid rather than the E2 or E3 components. We next used circular dichroism (CD) to monitor the formation of 1',4'iminophosphonoadipoyl-ThDP at ~305nm, a reporter of the tetrahedral predecarboxylation intermediate in ThDP-dependent enzymes (25) (26) (27) . We showed that the positive CD305 signal depended on the concentration of adipoylphosphonic acid (Figures S2k−m) and displayed saturation of the DHTKD1 active centers by adipoylphosphonic acid at a molar ratio of 1.87 (with much less or no saturation of the OGDH active centers ( Figures S2n−r) ). These data demonstrate stoichiometric binding of adipoylphosphonic acid in the active centers of DHTKD1, a finding that correlates with the loss of OADHc activity. Thus, adipoylphosphonic acid is a mechanism-based, activecenter-directed potent, tight-binding inhibitor of DHTKD1. To test whether this compound could inhibit DHTKD1 in cells, we treated HEK-293 cells and looked at the levels of AAA, the transamination product of the DHTKD1 substrate OA ( Figure S1 ). Adipoylphosphonic acid dose dependently increased the level of AAA in HEK-293 cells, demonstrating the successful inhibition of DHTKD1 in a cellular model (Figures S2s and t).
Identification of tenatoprazole as a DHTKD1 inhibitor through HTS
In order to identify DHTKD1 inhibitors with drug-like properties, we developed and performed a high-throughput screen (HTS, Supplemental Figures S7-S10). The class of compounds that were consistently identified as DHTKD1 inhibitors in the screen were benzimidazole and imidazopyridine proton-pump inhibitors, with tenatoprazole being most potent (IC50, 27 ± 1 M) ( Figure 2a ). Analysis of several omeprazole analogs, including sulfones and sulfides highlighted the importance of the sulfoxide group in the DHTKD1 inhibition process ( Figure S3 ). Tenatoprazole displayed kinetics most compatible with a noncompetitive inhibition of DHTKD1 (Ki = 83 ± 34 M) (Figure 2a and Figures S4a and b ). We then analyzed the drug-protein interaction by differential scanning fluorimetry (DSF) . Surprisingly, tenatoprazole destabilized the protein, decreasing the melting temperature by over 3 degrees (250 M) or 5 degrees (500 M) ( Figure 2b and Figure S4c ), an effect absent in the presence of dithiothreitol (DTT, Figure S4d ). We compared the other omeprazole analogs in the same assay and found that destabilization tracked with the IC50 values of the inhibitors, with tenatoprazole showing the largest destabilization of all the compounds (Figure 2b ). Tenatoprazole was unable to inhibit OADHc, likely due to the presence of DTT in the assay mixture.
Tenatoprazole increased AAA levels ( Figure 2c ) without major effects on other amino acids indicating the inhibition of DHTKD1 is rather specific ( Figure S4e ).
Structure of DHTKD1
We obtained a crystal structure of human DHTKD1 at 2.1 Å (Figure 3a ) using the M. smegmatis KGD structure as a search model for molecular replacement. The cofactor ThDP was present and bound to several residues in the active site, making several key presumed hydrogen bonds ( Figure 3b ). DHTKD1 crystallized as a dimer ( Figure 3a and Table S2 ), similar to the M. smegmatis homolog, with the two monomers twisted around each other and two active sites formed at the interface. We believe that the minimal functional unit is a dimer, which is evidenced by several observations. First, we note that each of the two active sites in the dimer comprises residues from both copies of the protein, with one chain providing residues for binding the phosphate moieties and the other for the thiamin (Figure 3b ). It is unlikely that a single copy can bind ThDP fully.
Secondly, there is a magnesium coordinating E641 from each monomer, which is suggestive of a stable ionic interaction ( Figure 3c ). Thirdly, we note that the surface area of the interface between the two monomers is extensive. According to the PISA server, the interface covers over 5000 Å 2 of area with a predicted G of -29.6 kcal/mol, suggestive of a strong interaction between the two copies (28) . It is likely that the full complex stabilizes the dimer further.
The tightly packed dimer still leaves room for the substrates to be solvent accessible, so they can be transferred to the other components of the complex ( Figure   S5a ). While the active site is conserved between M. smegmatis and human ( Figure   S5b ), we note two major differences. The human protein has a smaller serine (Ser 288) in the active site instead of tyrosine, which provides more room compared to the M. smegmatis protein ( Figures S5c and d) , which may explain the ability of the protein to accept larger substrates such as OA and OP. Additionally human DHTKD1 has a Tyr residue at position 190, which differs from the Phe residue found in the M. smegmatis protein and other proteins of the OGDH family, and is predicted to be implicated in substrate binding. We studied the possible binding mode of the preferred DHTKD1 substrates (OA and OP) and the inhibitor adipoylphosphonic acid by docking the compounds into the crystal structure of the protein. Using induced fit docking (IFD), to allow for small adjustments in the protein structure, we obtained a binding mode for OA that is compatible with the formation of a pre-decarboxylation intermediate at the C2 thiazolium atom of ThDP ( Figure S5e ). The substrate is positioned in the active site by a series of hydrogen bonding interactions with the side chains of Lys 188, Tyr 190, His 435, Asn 436, and His 708. The same interactions were observed in the docking pose of OP (not shown). IFD of the adipoylphosphonic acid inhibitor showed that it mimics the substrate binding mode resulting in a pose that is compatible with the formation of the decarboxylation nucleophilic adduct suggested by the experimental data ( Figure S5f ).
Analysis of known DHTKD1 missense variants
Next, we studied all reported missense variants in DHTKD1 (Figure 4a) (7 variants reported in AMOXAD patients (2, 3, 6) and 3 variants associated with EoE (10)) ( Figures   S6a and b) . The S777P and S862I variants were largely insoluble and the small amounts of soluble protein exhibited severe proteolysis during expression and purification. This indicates that the mutations prevent proper folding of the protein. In the crystal structure, the S862 sidechain makes important contacts to sidechains in two different parts of the protein, T917 and H812. Losing these contacts and inserting the bulkier hydrophobic isoleucine likely inhibits protein folding. For S777, there is a likely hydrogen bond between the serine sidechain and the backbone of neighboring L589.
The mutation at this position eliminates this interaction as well as introduces a proline, which can destabilize the current backbone conformation due to its different preference in , dihedral angles.
For the 8 other DHTKD1 variants, we analyzed steady-state kinetic parameters and thermal stability (Table 1 and Figure S6c ). Three variants displayed a higher propensity to form insoluble protein (L234G, R455Q and R715C), but enough soluble protein was recovered to establish that they were inactive. Two variants (V360A and P773L) showed a decrease catalytic efficiency (1.2-and 2.7-fold decrease, respectively) due to a lower Vmax when compared with wild-type. Three variants (R163Q, Q305H and G729R) showed kinetic properties similar or slightly improved compared with wild-type (1.3-, 1.7-and 1.6-fold increase in catalytic efficiency, respectively). Substrate affinity was not changed in any of the variants.
The observed DHTKD1 variants are spread throughout the protein and generally avoid the ThDP binding site ( Fig. 4a ). All 8 soluble variants were stable enough to determine the melting temperature by DSF testing (Figure 4b ). Q305H and G729R had statistically insignificant changes on the Tm of the protein suggesting that their effects are not structural. L234G, V360A, and P773L had decreased Tm values. V360 is in the core of the protein and reducing its size likely destabilizes the hydrophobic packing of the protein as observed in other enzymes (29) . L234G and P773L likely cause problems in folding by altering to glycine or from proline, which have unique dihedral angle preferences as mentioned above. The remaining 3 variants had relatively small, but reproducible changes with an increase in stability for R455Q and R715C, and a decrease in stability for R163Q. R455 forms a salt bridge with D400 and a hydrogen bond with T430 while R715 makes a salt bridge with D677 and a hydrogen bond with Q673. Mutation of these residues likely abrogates activity by disrupting these important interactions. For Q305H, G729R, but also R163Q, we can likely rule out protein folding as causative. Given that these variants are active, we speculate that they affect assembly or substrate exchange with the E2 or E3 components of OADHc. The G729 and R163 residues are indeed on the surface. Q305 is near the surface but makes important internal contacts, so it is unclear how it could maintain activity, but perhaps the substitution to His maintains these contacts but interferes with the complex.
Discussion
Here we employed a DHTKD1 specific enzyme assay to enable screening for inhibitors.
We found that not only OA, but also OP are good substrates for DHTKD1. The affinity for OA was higher, whereas the Vmax was higher with OP. Virtually no activity was observed with OG and OS. Interestingly, in vitro reconstituted OADHc (DHTKD1, DLST and DLD) did show activity toward OG (4). This apparent inconsistency is likely explained by Succinylphosphonic acid is a known inhibitor of OGDHc (4, 30) . We have chemically synthesized adipoylphosphonic acid, which is the phosphonic acid analog of the DHTKD1 substrate OP. We have shown that adipoylphosphonic acid acts as a mechanism-based, active site directed tight-binding inhibitor of OADHc, and a much weaker one of the OGDHc. Adipoylphosphonic acid lacks chemical properties to be developed as a drug, but is a molecule that can be used in vitro and in whole cell systems. Through HTS, we identified the class of benzimidazole/imidazopyridine protonpump inhibitors as inhibitors of DHTKD1. Tenatoprazole is a noncompetitive inhibitor of DHTKD1, possibly binding to an allosteric site in the enzyme. We note that tenatoprazole causes an unusually large destabilization of DHTKD1 as measured by DSF, which indicates structural alterations upon binding. We were unable to co-crystallize tenatoprazole with DHTKD1 in the same crystal form consistent with the possibility that tenatoprazole alters the conformation of the protein.
Whereas structures homologous to DHTKD1 have been reported for distant species such as M. smegmatis (KGD) and E. coli (SucA), we report the first eukaryotic structure for an E1 enzyme. The human structure provides valuable information on the possible mechanism of amino acid substitutions associated with human disease. We expressed all missense mutations that have been associated with AMOXAD and EoE.
Five out of the seven DHTKD1 autosomal recessive missense variants associated with AMOXAD showed defects in folding, function or thermal stability. S777P was insoluble, L234G, R455Q and R715C were inactive and P773L presented a lower catalytic activity and thermal stability. Fibroblasts from an AMOXAD patient with compound heterozygosity for R455Q/S777P did not display any immunoreactivity for DHTKD1 (3), which is consistent with our analysis of these two variants. The Q305H and G729R variants, however, did not display any defects in folding, activity and thermal stability.
Other possible mechanisms not tested in our studies include a negative impact of the mutation on the assembly with other components of the complex or in the substrate exchange between these components.
The three autosomal dominant missense variants associated with EoE have quite distinct properties. R163Q behaves similar to the wild type protein, V360A had a lower catalytic efficiency and thermal stability and S862I was insoluble. EoE is a chronic allergic inflammatory esophageal disorder and it remains unclear how DHTKD1 variants can produce a dominant effect leading to mitochondrial dysfunction as implicated in the pathogenesis of this disease (10) . A possible effect on the assembly of the OADHc and the recently described hybrid complex with OGDHc (8) remains to be demonstrated.
Alternatively, the EoE mutations could lead to a conformation-driven gain-of-function mechanism, as has recently been demonstrated for mutations in the aminoacyl-transfer RNA (tRNA) synthetases associated with CMT (31).
In summary, we determine the crystal structure of human DHTKD1, an enzyme associated with AMOXAD, CMT2Q and EoE, which are 3 clinically distinct disorders. We Cells were grown in LB medium with kanamycin (25 g/ml for pET-28a) and chloramphenicol (35 g/ml for Rosetta cells). A culture for protein production was inoculated 1 in 1000 with a fresh overnight culture and cells were grown at 37°C with shaking for 3-4 h with regular determination of the optical density at 600 nm (OD600).
Once the culture reached an OD600 of 0.6-0.7, the culture was placed at RT, and protein production was induced by adding IPTG to a final concentration of 1 mM. Protein production was continued overnight, after which the cells were harvested by centrifugation and stored at -20 °C. Protein extracts were prepared using BugBuster High-throughput screening. In order to identify DHTKD1 inhibitors with drug-like properties, we developed and performed a high-throughput screen based on the DHTKD1 activity assay ( Figures S2a and S7a) . We evaluated the robustness of the assay by performing a pilot screen of ~4000 molecules from a drug and bioactive collection and ~600 molecules from a diversity collection (ChemBridge). The screen was robust with a good assay window and percent coefficient of variance % CV < 5% and Z′ of 0.84 ± 0.10 ( Figure S7b) (38) . When considering compounds with inhibition greater than 3SD above the mean, the hit rate for drug (38 hit compounds, 1.7%) and bioactives (26 hit compounds, 1.4%) was significantly higher when compared to the lower hit rate for diversity molecules (5 hit compounds, 0.8%) ( Figures S7c and d) .
We then screened against a diversity library, a collection of 125,465 compounds from three libraries (ChemBridge, ChemDiv and CB Premium). Using a threshold criterion for inhibition greater than or equal to 3SD above the mean (Bscore, inhibition and standard score), we identified 320 hit compounds (pilot screen and HTS) ( Figure   S8a ). This group included 257 singletons and 63 compounds in 26 clusters (≥2 members with similar structure) and corresponds to a hit rate of ~0.25%. Additional filtering resulted in a final number of 133 hit compounds (106 singletons and 27 compounds in 11 clusters, a hit rate of ~0.17%) ( Figure S8b ). We then selected 192 hit molecules from the primary screen (including all 133 hits after row exclusion and 59 after additional review but before row exclusion) for testing in a concentration-response inhibition assay. 40 out of the 192 hit molecules showed dose-response curves ( Figure S9 ). 16 of these molecules had IC50 ≤30 M, and 13 were commercially available and advanced to the repurchase and re-evaluation phase ( Figure S10) . absorbance at 600 nm). Each plate included mock (no enzyme) and positive (adipoylphosphonic acid) controls. Assay performance was measured by z-prime (Z′), a dimensionless factor used to assess the quality of a HTS (38) . Hit selection was based on dependent (% inhibition) and independent (B score and standard score) activity parameters. The hit selection threshold was set at calculate mean + 3SD and candidates must satisfy statistical criteria for all three parameters. Standard score (or z-score:
(inhibition-mean)/SD)) and Bscore were measured as defined by Brideau et al. (39) .
Additional further filtering of the screening hits was done by removing systematic influences (e.g. pattern of high absorbance/apparently inhibited rows). Compounds identified in the primary screen were cherry picked for dose-response assays. 150 nL of each compound was transferred by pin tool to each well with concentration ranging from 58 nM to 30 M. Primary screen results were analyzed using the UCSF SMDC webbased application HiTS. This web-based analysis platform provides a data analysis interface for viewing primary screen and dose-response results. Data analysis for doseresponse inhibition experiments was carried out in GraphPad Prism 7 and curves were fit to a standard inhibition log dose-response curve to yield an IC50 value. The protein did not produce diffracting crystals initially, so we then methylated the protein to improve crystal packing. Lysines were methylated following the method of Walter et al (41) . 20 L of freshly prepared 1 M dimethylamine-borane complex (DMAB) and 40 L of 1 M formaldehyde (HCHO) were added to 1 ml of 10 mg/ml of DHTKD1 in a 1.5 ml Eppendorf tube. The tube was covered with aluminum foil and the reactions were gently mixed and incubated for 2 hrs in cold room in that covered tube. Addition of DMAB and HCHO followed by 2 hrs of incubation were repeated twice. Finally, 10 L of DMAB was added and the reaction was incubated overnight at 4 °C in the cold room.
Assessment of DHTKD1 inhibitors in HEK-293 cells by amino acid analysis. HEK-
The next day, the methylation reaction was quenched by adding 125 L of 1 M Tris, pH 7.5. Occasionally, this reaction caused some amount of proteins to be precipitated, which was removed by high speed centrifugation prior to size exclusion chromatography.
Following methylation, the protein was then purified by gel filtration on a Superdex 200 increase column (GE Lifescience) in a buffer of 20 mM Tris-HCl pH 8.0, 100 mM KCl, 1 mM MgCl2, 1 mM DTT and 0.5 mM ThDP. Protein was then concentrated to approximately 10 mg/ml and flash frozen in liquid nitrogen.
Crystallization and structure determination. After screening crystal conditions, crystals were grown by the hanging drop vapor diffusion method by mixing 1 l protein with 1 l of reservoir containing 0.1 M magnesium acetate, 0.1 M MOPS pH 7.5, and 12% PEG 8000 and 10% glycerol. Crystals were flash frozen in liquid nitrogen before collecting at the AMX (17-ID-1) beamline at NSLS II at Brookhaven National Laboratory.
Data was processed using autoproc (42) and scaled with Aimless (43) . The structure was solved by molecular replacement, using the structure of the M. smegmatus 2oxoglutarate dehydrogenase protein as a search model (PDB code 3ZHQ) using the program Phaser (44) after making a homology model using Phenix Sculptor (45) . After molecular replacement, we performed multiples rounds of building using Phenix Autobuild (46) . The models were subsequently refined using Phenix (47) , with rigid body refinement and multiple rounds of simulated annealing, minimization, atomic displacement parameter (ADP or B-factor) refinement and TLS refinement (determined using the TLSMD server (48, 49) ), with interspersed manual adjustments using Coot (50) . Geometric restraints for N-methyl-lysine were generated with Phenix Elbow (51), and these restraints were used throughout refinement. All structural figures were made with Pymol (52).
Ligand Docking. The crystal structure of DHTKD1 was prepared for docking using the Protein Preparation wizard in Maestro (Schrödinger) to add missing atoms, optimize hydrogen bonds, and minimize the structure (heavy atom convergence to RMSD 0.3 Å).
Structures of ligands were prepared using ligprep (Schrödinger) with the OPLS3e force field and Epik ionization. Induced Fit Docking was carried out with Glide/Prime (Schrödinger) using the standard protocol and docking box centered on the active site of the crystal structure. Figures were generated using PyMOL (Schrödinger).
Site-specific mutagenesis and protein expression and purification of DHTKD1
variants. The DHTKD1 variants were constructed using the QuikChange ® II site-directed mutagenesis kit (Thermo Fisher Scientific Inc., MA, USA), the pET28a(+) vector encoding DHTKD1 as template and specific oligonucleotide primers listed in Table S3 .
Authenticity of the mutagenesis was verified by DNA sequencing. Statistics. Data are displayed as the mean ± the standard deviation (SD). Differences between groups were evaluated using a one-way analysis of variance with Bonferroni's multiple comparison test (GraphPad Prism 7). Significance is indicated as follows: *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. 
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